ILLUMINA, INC. 8K

Illumina announced stronger-than-expected Q2 2026 results and raised its full-year 2026 revenue and earnings guidance, driven by robust demand for its sequencing products.

Illumina, Inc. reported its financial results for the second quarter of fiscal 2026, announcing revenue of $1.16 billion (up 9.5% year over year and 8.1% on a rest-of-world organic basis excluding China, currency, and acquisitions), GAAP operating margin of 21.1%, GAAP diluted EPS of $1.35 (non-GAAP EPS of $1.31), and free cash flow of $162 million, while also raising its full‑year 2026 guidance to projected revenue of $4.60–$4.64 billion, non-GAAP operating margin of 23.4%–23.6%, and non-GAAP diluted EPS of $5.30–$5.40, citing continued strong demand for its NovaSeq X platform and progress integrating SomaLogic assets.

Filing Facts

CIK

1110803

Ticker

ILMN

Form

8K

Source Type

sec

Accession

0001110803-26-000155

Alert Tier

7